News
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafonnée à 3 millions d’euros
NFL Biosciences annonce une levée de fonds réussie de 3 millions d'euros pour financer son candidat médicament contre l'addiction au tabac. Allocation des fonds pour une étude de Phase 3 de NFL-101 -
COMMUNIQUÉ RÉGLEMENTÉ
NFL Biosciences announces the success of its capital increase capped at €3 million
NFL Biosciences successfully completes €3 million capital increase with oversubscription, involving international and French investors; plans Phase 3 clinical trial for smoking cessation drug NFL-101 -
-
-
COMMUNIQUÉ DE PRESSE
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog
Curatis Holding AG reveals Corticorelin as active substance of C-PTBE-01, targeting larger patient group for PTBE treatment. Strengthened team with Dr. Kirsty Crame and Dr. Timm Trenktrog. Market opportunity in PTBE surpassing USD 1 billion -
-
COMMUNIQUÉ DE PRESSE
PolyPeptide announces expansion of existing credit facilities
PolyPeptide Group AG secures EUR 40 million additional financing under existing credit facilities, supported by main shareholder Draupnir Holding B.V., enhancing financial flexibility for growth towards doubling revenue by 2028 -
-
